Evista (Raloxifene) – 28 tb/60 mg – Substipharm – expires 2031

Description

Raloxifene is one of the newer anti-estrogens on the market for the treatment of Estrogen-related medical indications. Raloxifene prevents gynecomastia by blocking estrogen receptors in the breast tissue. It occupies the estrogen receptor sites on the breast tissue, leaving no space for the incoming, growth-stimulating estrogens to attach to, effectively reducing breast volume. Multiple studies corroborate this claim. A 3-to-9 month Raloxifene treatment course decreased gynecomastia by up to 86% in one study. Another study found that the majority of users who took Raloxifene experienced no severe side effects.

Dosage:

60mg/day throughout the steroid or prohormone cycle